These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31043468)

  • 41. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
    Tantisiriwat W; Linasmita P
    J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
    Heil EL; Johnson JK
    J Clin Microbiol; 2016 Apr; 54(4):840-4. PubMed ID: 26791363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
    Liu PY; Shi ZY; Tung KC; Shyu CL; Chan KW; Liu JW; Wu ZY; Kao CC; Huang YC; Lin CF
    J Infect Dev Ctries; 2014 Mar; 8(3):289-96. PubMed ID: 24619258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
    Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.
    Bailey AL; Armstrong T; Dwivedi HP; Denys GA; Hindler J; Campeau S; Traczewski M; Humphries R; Burnham CA
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29976590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.
    Bartsch SM; Huang SS; Wong KF; Slayton RB; McKinnell JA; Sahm DF; Kazmierczak K; Mueller LE; Jernigan JA; Lee BY
    J Clin Microbiol; 2016 Nov; 54(11):2757-2762. PubMed ID: 27582516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic susceptibility of common pediatric uropathogens in the United States.
    Tamma PD; Sklansky DJ; Palazzi DL; Swami SK; Milstone AM
    Clin Infect Dis; 2014 Sep; 59(5):750-2. PubMed ID: 24825869
    [No Abstract]   [Full Text] [Related]  

  • 49. Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae.
    Bunnell KL; Wenzler E; Harrington AT; Danziger LH
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):335-336. PubMed ID: 29395714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
    Cantón R; Canut A; Morosini MI; Oliver A
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use].
    Jónsdóttir K; Kristinsson KG
    Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.
    Sader HS; Rhomberg PR; Huband MD; Critchley IA; Stone GG; Flamm RK; Jones RN
    J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29563198
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.
    Karlowsky JA; Kelly LJ; Thornsberry C; Jones ME; Evangelista AT; Critchley IA; Sahm DF
    Int J Antimicrob Agents; 2002 Jan; 19(1):21-31. PubMed ID: 11814764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].
    Žemličková H; Jakubů V; Fridrichová M
    Klin Mikrobiol Infekc Lek; 2017 Dec; 23(4):132-135. PubMed ID: 29378381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.
    Morosini MI; García-Castillo M; Loza E; Pérez-Vázquez M; Baquero F; Cantón R
    J Clin Microbiol; 2005 Sep; 43(9):4480-5. PubMed ID: 16145095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antimicrobial susceptibility of Pseudomonas aeruginosa in China: a review of two multicentre surveillance programmes, and application of revised CLSI susceptibility breakpoints.
    Xiao M; Wang Y; Yang QW; Fan X; Brown M; Kong F; Xu YC
    Int J Antimicrob Agents; 2012 Nov; 40(5):445-9. PubMed ID: 22910455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anatomic, Geographic, and Taxon-Specific Relative Risks of Carbapenem Resistance in the Health Care System of the U.S. Department of Defense.
    Lesho E; Chukwuma U; Sparks M; Neumann C; Richesson D; Clifford R; Gierhart S; Waterman P; Hinkle M
    J Clin Microbiol; 2016 Jun; 54(6):1546-1551. PubMed ID: 27030488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [From Pneumococcus to Pseudomonas: the antibacterial behaviour through the time].
    Rossolini GM
    Infez Med; 2009 Dec; 17 Suppl 5():5-12. PubMed ID: 20424531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in antimicrobial susceptibility breakpoints for Pseudomonas aeruginosa, isolated from blood cultures, set by the Clinical and Laboratory Standards Institute (CLSI) and the Japanese Society of Chemotherapy.
    Nakamura T; Shimizu C; Kasahara M; Nakata C; Munakata M; Takahashi H
    J Infect Chemother; 2007 Feb; 13(1):24-9. PubMed ID: 17334725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.